Predict your next investment

Corporation
HEALTHCARE | Biotechnology
callistopharma.com

See what CB Insights has to offer

Founded Year

1996

Stage

Acquired | Acquired

Total Raised

$4.84M

About Callisto Pharmaceuticals

Callisto Pharmaceuticals is a biopharmaceutical company focused on the development of drugs to treat multiple myeloma (an incurable blood cancer that invades and proliferates in bone marrow), and osteolytic bone disease, among other cancers. The Company's lead drug candidate, Atiprimod, is a small-molecule, orally available drug with antiproliferative and antiangiogenic activity. The Company was formed, in April 2003, through a reverse acquisition between Callisto Pharmaceuticals and Webtronics.In January 2013, Callisto Pharmaceuticals was acquired by Synergy Pharmaceuticals. The valuation of Callisto Pharmaceuticals was undisclosed. Other terms of the deal were not released.

Callisto Pharmaceuticals Headquarter Location

420 Lexington Avenue Suite 1609

New York, New York, 10170,

United States

212-297-0010

Latest Callisto Pharmaceuticals News

Asia-Pacific Neuroendocrine Tumors Market Analysis, Leading Players, Future Growth, Business Prospects Research Report Foresight To 2028 – Novartis AG, Ipsen Pharma, Viatris Inc., Callisto Pharmaceuticals, Eli Lilly and Company

Jul 21, 2021

Search jobs 21-Jul-2021 Asia-Pacific Neuroendocrine Tumors Market Analysis, Leading Players, Future Growth, Business Prospects Research Report Foresight To 2028 – Novartis AG, Ipsen Pharma, Viatris Inc., Callisto Pharmaceuticals, Eli Lilly and Company The wide-ranging Asia-Pacific Neuroendocrine Tumors Market analysis report will be favorable for newcomers/new investors, propose investors and private equity enterprises, analysts and prudent business organizers, suppliers, manufacturers, and distributors, and end-use industries. This research report also analyzes other significant trends and market drivers that will influence market growth over 2021-2028. A detailed market research study of this market document focuses on several essential parameters related to the market that includes but are not limited to a competitive landscape, brief segmentation, and industrial infrastructure. The large-scale Asia-Pacific Neuroendocrine Tumors Market report represents all the regions as well as countries across the globe, which showcase a regional manufacturing status, such as volume, market size, value, and price details. Furthermore, the report also illustrates major prime vendors, associated with their valuable share, value, capacity, company profiles, and essential shares engaged by each company. This overall market report is classified by the primitive players, applications, types, and geographical areas. The credible Asia-Pacific Neuroendocrine Tumors Market report gives details of financial outlook, the analysis of the new product, differentiable business strategies as well as revolutionary marketing trends. Get a Sample Copy of the Report to understand the structure of the complete report (Including Full TOC, Table & Figures): https://www.databridgemarketresearch.com/request-a-sample/?dbmr=asia-pacific-neuroendocrine-tumors-market Neuroendocrine tumors market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 11.5% in the forecast period of 2021 to 2028 and is expected to reach USD 929.49 million by 2028. Strategic initiatives by market players and advent of mass vaccination programmes for neuroendocrine tumors are likely to be the major drivers which propelled the demand of the market in the forecast period. Market Key Competitors: Market Segmentation: Asia-Pacific Neuroendocrine Tumors Market, By Classification (Functional Net and Non-Functional Net), Site (Lung, Pancreas, Gastrointestinal Tract (GI), Grade (Grade 1 {Low-Grade Tumor}, Grade 2 {Intermediate-Grade Tumor}, Grade 3 {High-Grade Tumor}), Type (Diagnosis and Treatment), Route of Administration (Oral and Parenteral), Mode of Purchase (Prescription and Over the Counter (OTC)), End User (Hospitals, Specialty Clinics, Radiation Centers, Home Healthcare and Others), Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others), Country (China, Japan, India, Australia, South Korea, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, rest of Asia-Pacific) Industry Trends and Forecast to 2028 By Region Europe (Germany, France, UK, Russia, and Italy) Asia-Pacific (China, Japan, Korea, India, and Southeast Asia) South America (Brazil, Argentina, Colombia, etc.) The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa) Request for Free Full TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=asia-pacific-neuroendocrine-tumors-market The neuroendocrine tumors market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal. List of figures: FIGURE 2 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: DATA TRIANGULATION FIGURE 3 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: DROC ANALYSIS FIGURE 4 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: ASIA-PACIFIC VS REGIONAL ANALYSIS FIGURE 5 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: COMPANY RESEARCH ANALYSIS FIGURE 6 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: INTERVIEW DEMOGRAPHICS FIGURE 7 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: DBMR MARKET POSITION GRID FIGURE 8 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: VENDOR SHARE ANALYSIS FIGURE 9 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: MARKET END USER COVERAGE GRID FIGURE 10 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: SEGMENTATION FIGURE 11 INCREASED AWARENESS OF NEUROENDOCRINE TUMORS CASES IS EXPECTED TO DRIVE THE ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET IN THE FORECAST PERIOD OF 2021 TO 2028 FIGURE 12 NON-FUNTIONAL NET SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET IN 2021 & 2028 FIGURE 13 FIVE YEAR SURVIVAL RATE OF PANCREATIC NEUROENDOCRINE TUMOR BETWEEN 2010- 2016 FIGURE 14 INCIDENCE OF NEO-ENDOCRINE NEOPLASM IN CHINA, EUROPE AND U.S. FIGURE 15 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: BY CLASSIFICATION, 2020 —————- TABLE 1 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, PIPELINE ANALYSIS TABLE 2 SALES DATA OF ONCOLOGY MARKET FOR 2019/2020 TABLE 3 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION 2019-2028(USD MILLION) TABLE 4 ASIA-PACIFIC NON-FUNCTIONAL NET IN NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION 2019-2027 (USD MILLION) TABLE 5 ASIA-PACIFIC FUNCTIONAL NET IN NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION 2019-2027 (USD MILLION) TABLE 6 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY SITE 2019-2028 (USD MILLION) TABLE 7 ASIA-PACIFIC GASTROINTESTINAL TRACT (GI) IN NEUROENDOCRINE TUMORS MARKET, BY SITE 2019-2028 (USD MILLION) TABLE 8 ASIA-PACIFIC LUNGS IN NEUROENDOCRINE TUMORS MARKET, BY SITE 2019-2028 (USD MILLION) TABLE 9 ASIA-PACIFIC PANCREAS NEUROENDOCRINE TUMORS MARKET, BY SITE 2019-2028 (USD MILLION) TABLE 10 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY GRADE 2019-2028 (USD MILLION) TABLE 11 ASIA-PACIFIC GRADE 2 (INTERMEDIATE-GRADE TUMOR) IN NEUROENDOCRINE TUMORS MARKET, BY GRADE 2019-2028 (USD MILLION) TABLE 12 ASIA-PACIFIC GRADE 3 (HIGH-GRADE TUMOR) IN NEUROENDOCRINE TUMORS MARKET, BY GRADE 2019-2028 (USD MILLION) TABLE 13 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY GRADE 2019-2028 (USD MILLION) TABLE 14 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION) TABLE 15 ASIA-PACIFIC DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION) TABLE 16 ASIA-PACIFIC DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION) TABLE 17 ASIA-PACIFIC IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION) TABLE 18 ASIA-PACIFIC TREATMENT NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION) TABLE 19 ASIA-PACIFIC TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION) TABLE 20 ASIA-PACIFIC SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION) —————– Thanks for reading this article, you can also get individual chapter-wise sections or region-wise report versions like North America, Europe, or Asia. Key Offerings: -Market Dynamics – Leading trends, growth drivers, restraints, and investment opportunities -Market Segmentation – A detailed analysis by product, by types, end-user, applications, segments, and geography -Competitive Landscape – Top key vendors and other prominent vendorsInquire More about This Report, Visit At: https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=asia-pacific-neuroendocrine-tumors-market Neuroendocrine Tumors Market Country Level Analysis The neuroendocrine tumors market is analysed and market size information is provided classification, site, grade, type, route of administration, end user and distribution channel as referenced above. The countries covered in the neuroendocrine tumors market report are China, Japan, India, Australia, South Korea, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, rest of Asia-Pacific. Asia-Pacific is expected to grow with the highest CAGR in the forecast period. China is expected to dominate in the market as the demand for neuroendocrine tumors product is increasing very rapidly with the urbanization and laboratory automation. The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data. Reason to Buy: Develop/modify business expansion plans by using substantial growth offering developed and emerging markets. Scrutinize in-depth global market trends and outlook coupled with the factors driving the market and those hindering it. Enhance the decision-making process by understanding the strategies that underpin commercial interest concerning products, segmentation, and industry verticals. About Data Bridge Market Research An absolute way to forecast what the future holds is to comprehend the trend today! Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to complex business challenges and initiates an effortless decision-making process. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate. Data Bridge Market Research UK: +44 208 089 1725 Hong Kong: +852 8192 7475

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Callisto Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Callisto Pharmaceuticals is included in 1 Expert Collection, including Cancer.

C

Cancer

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.